Rheumatoid Arthritis Drugs Market Report 2026

The rheumatoid arthritis drugs market size has grown marginally in recent years. It will grow from $60.1 billion in 2025 to $61.13 billion in 2026 at a compound annual growth rate (CAGR) of 1.7%. The growth in the historic period can be attributed to rising prevalence of rheumatoid arthritis, increased awareness and diagnosis rates, expansion of healthcare infrastructure, strong adoption of traditional DMARDs, favorable reimbursement for established therapies.

The rheumatoid arthritis drugs market size is expected to see steady growth in the next few years. It will grow to $67.49 billion in 2030 at a compound annual growth rate (CAGR) of 2.5%. The growth in the forecast period can be attributed to growing demand for biologics and BRMs, increasing uptake of biosimilars, advancement in precision medicine, expansion of online pharmacy channels, rising geriatric population. Major trends in the forecast period include expansion of biologic and targeted therapies, growing adoption of early and aggressive treatment strategies, increasing use of combination drug regimens, rising focus on personalized treatment protocols, growth of biosimilars in rheumatoid arthritis care.

The expanding elderly population is anticipated to drive the growth of the rheumatoid arthritis drugs market in the coming years. The elderly population includes individuals aged 65 years or older, who represent an increasing proportion of the overall population. This demographic transition is largely attributed to rising life expectancy and falling fertility rates, leading to a higher number of older adults worldwide. As rheumatoid arthritis occurs more frequently in older people, the growth of this age group increases demand for effective RA treatments, particularly newer therapies such as JAK inhibitors and targeted synthetic DMARDs that may offer improved tolerability for older patients. For example, in January 2024, according to the Population Reference Bureau, a Kenya-based nonprofit organization, the number of Americans aged 65 and above is projected to increase from 58 million in 2022 to 82 million by 2050, representing a 47% rise. The share of this age group within the total population is also expected to grow from 17% to 23% over the same period. As a result, the rising elderly population is contributing to the expansion of the rheumatoid arthritis drugs market.

Leading companies in the rheumatoid arthritis drugs market are concentrating on the development of advanced therapies, including flexible-dose methotrexate injections, to improve treatment effectiveness, enhance patient safety, and provide more convenient administration methods. Flexible-dose methotrexate injections are available in multiple strengths for adult patients with active RA, allowing personalized dosing and improved control of disease progression. For instance, in December 2023, China Medical System Holdings Limited, a China-based investment holding company primarily involved in pharmaceutical manufacturing, received acceptance from the National Medical Products Administration for its New Drug Application for an additional rheumatoid arthritis indication of Methotrexate Injection. Intended for adult RA patients, clinical trial results showed that the injection was not inferior to methotrexate tablets, with evidence of earlier and enhanced efficacy along with reduced gastrointestinal side effects. The injection is already approved for severe psoriasis in China and is marketed in more than 40 countries, highlighting its established clinical value and broad international presence.

In October 2023, Amgen PLC, a US-based biotechnology company, completed the acquisition of Horizon Therapeutic Plc for $27.8 billion. This acquisition enhances Amgen’s inflammation-focused portfolio by incorporating first-in-class medicines that are still early in their product lifecycle and target rare inflammatory conditions. Horizon Therapeutic PLC is an Ireland-based biopharmaceutical company that offers therapies for focal segmental glomerulosclerosis, kidney transplant rejection, and rheumatoid arthritis.

Major companies operating in the rheumatoid arthritis drugs market are Pfizer Inc., AbbVie Inc., Amgen Inc., Novartis AG, Eli Lilly and Company, F-Hoffmann La Roche AG, Bristol-Myers Squibb Company, Johnson & Johnson Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A, Regeneron Pharmaceuticals Inc., Galapagos NV, Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, UCB S.A., Roche Holding AG, Mallinckrodt Pharmaceuticals, AstraZeneca PLC, Bayer AG.

North America was the largest region in the rheumatoid arthritis drugs market in 2025.North America is expected to be the fastest-growing region in the global rheumatoid arthritis market report during the forecast period. The regions covered in the rheumatoid arthritis drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the rheumatoid arthritis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the rheumatoid arthritis drugs market by increasing the cost of imported active pharmaceutical ingredients, biologics, and advanced manufacturing inputs, thereby impacting overall drug pricing and supply chain efficiency. Biologic response modifiers, janus kinase inhibitors, and parenteral formulations are most affected due to their complex production processes, with regions such as Asia-Pacific and Europe experiencing notable cost pressures. However, tariffs have also encouraged local manufacturing, regional sourcing of raw materials, and increased investment in domestic pharmaceutical production, supporting long-term market resilience and supply security.

The rheumatoid arthritis drugs market research report is one of a series of new reports that provides rheumatoid arthritis drugs market statistics, including rheumatoid arthritis drugs industry global market size, regional shares, competitors with a rheumatoid arthritis drugs market share, detailed rheumatoid arthritis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the rheumatoid arthritis drugs industry. This rheumatoid arthritis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Rheumatoid arthritis drugs are medications used to treat an autoimmune condition characterized by symptoms such as inflammation in the tissues surrounding the joints. These drugs help reduce long-term damage to joints and other tissues while slowing the overall progression of rheumatoid arthritis.

The primary categories of rheumatoid arthritis drugs include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying antirheumatic drugs (DMARDs), biologic response modifiers (BRMs), and other drug classes. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a group of medicines used to manage inflammation, fever, and related inflammatory disorders, while avoiding many of the side effects associated with steroids. The various routes of administration include oral, parenteral, topical, and other methods. Distribution channels for rheumatoid arthritis drugs include hospital pharmacies, retail pharmacies, and online pharmacies.

The rheumatoid arthritis drugs market consists of sales of products like abatacept, aceclofenac and adalimumab. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.